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Abstract
 
The cyclooxygenase-2 (COX-2) enzyme catalyzes the rate-limiting step of prostaglandin for-
mation in inflammatory states, and COX-2 overexpression plays a key role in carcinogenesis.
To understand the mechanisms regulating COX-2 expression, we examined its posttranscrip-
tional regulation mediated through the AU-rich element (ARE) within the COX-2 mRNA
3
 
 
 
-untranslated region (3
 
 
 
UTR). RNA binding studies, performed to identify ARE-binding
regulatory factors, demonstrated binding of the translational repressor protein TIA-1 to COX-2
mRNA. The significance of TIA-1-mediated regulation of COX-2 expression was observed in
TIA-1 null fibroblasts that produced significantly more COX-2 protein than wild-type fibro-
 
blasts. However, TIA-1 deficiency did not alter 
 
COX-2
 
 transcription or mRNA turnover.
Colon cancer cells demonstrated to overexpress COX-2 through increased polysome associa-
tion with COX-2 mRNA also showed defective TIA-1 binding both in vitro and in vivo.
These findings implicate that TIA-1 functions as a translational silencer of COX-2 expression
 
and support the hypothesis that dysregulated RNA-binding of TIA-1 promotes COX-2
expression in neoplasia.
Key words: COX-2 • cyclooxygenase-2 • prostaglandins • TIA-1 • AU-rich element
 
Introduction
 
Metabolites of arachadonic acid participate in normal and
aberrant growth responses, including chronic inflammation
and carcinogenesis (1). Cyclooxygenases are key enzymes
in the conversion of free arachidonic acid to prostaglandins.
The inducible isoform of cyclooxygenase, COX-2, is an
immediate-early response gene not expressed constitutively
in most cells. However, tight molecular regulation allows
for rapid COX-2 expression and increased prostaglandin
synthesis when necessary. Several lines of evidence demon-
strate that unregulated COX-2 expression occurs at multi-
ple stages in colon carcinogenesis and is important in the
promotion of tumorigenesis (1, 2). These findings, coupled
with recent evidence demonstrating the benefits of COX-2
inhibitors in many cancer models, underscore the signifi-
cance of aberrant COX-2 expression and suggest that phar-
macologic inhibition of COX-2 and/or regulation of its
expression may limit cancer progression.
COX-2 expression is regulated through both transcrip-
tional and posttranscriptional mechanisms (3). We previ-
ously identified an AU-rich element (ARE) within the 3
 
 
 
untranslated region (3
 
 
 
UTR) of COX-2 mRNA that con-
fers posttranscriptional regulation by controlling both mRNA
decay and protein translation (4, 5). The ability of this cis-
acting mRNA element to regulate COX-2 protein levels
and associated prostaglandin synthesis was observed in cells
maintaining low to undetectable COX-2 levels (4). In con-
trast, stabilization of COX-2 mRNA occurs in cancer cells,
implicating that loss of ARE-function promotes height-
ened COX-2 expression in neoplasia (3, 6).
Posttranscriptional regulation mediated by the COX-2
ARE is facilitated through trans-acting ARE-binding fac-
tors. These regulatory proteins form stable complexes with
the COX-2 3
 
 
 
UTR and regulate both COX-2 mRNA
stability and translation (4, 7). A number of ARE-binding
proteins have been identified with several proposed func-
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tions including promotion of rapid mRNA decay, increase
in mRNA stability, and regulation of translational effi-
ciency (8). For example, HuR protein binds to the COX-2
ARE and when overexpressed promotes the stabilization of
ARE-containing transcripts; this effect is observed in tu-
mors where HuR protein is overexpressed (6). In contrast,
AUF1/hnRNP D protein binding of the COX-2 ARE is
proposed to regulate rapid mRNA decay similar to other
ARE-containing transcripts (7). Thus, the relative abun-
dance of these functionally distinct ARE-binding proteins
can determine the fate of COX-2 transcript levels and im-
pact COX-2 protein levels.
We have identified the apoptosis-associated protein
TIA-1 as a regulator of COX-2 expression at the posttran-
scriptional level. Through its ability to bind the COX-2
ARE, this RNA-binding protein acts as a translational si-
lencer of COX-2 expression but does not affect mRNA
stability. More importantly, deficiencies in TIA-1 mRNA
binding are observed in colon cancer cells overexpressing
COX-2 protein through increased polysome association
with COX-2 mRNA. These findings suggest that misregu-
lated association of the TIA-1 RNA-binding protein with
COX-2 mRNA contributes to enhanced expression and
perhaps the overall neoplastic potential of cancer cells.
 
Materials and Methods
 
Cell Culture and DNA Transfections.
 
HeLa, HT29, and LoVo
cells were maintained in DMEM containing 10% FBS. Wild-type
(TIA-1
 
 
 
/
 
 
 
) and TIA-1 deficient (TIA-1
 
 
 
/
 
 
 
) primary mouse em-
bryonic fibroblasts (MEFs) were prepared as described previously
(9). MEFs were grown in DMEM containing 10% FBS and used
before exceeding 8 passages. TIA-1
 
 
 
/
 
 
 
 MEFs stably transfected
with a human TIA-1 cDNA were prepared as described previ-
ously (10). MEFs were transfected with a 1.8-kb human COX-2
promoter luciferase reporter construct (6) along with control
pSV-
 
 
 
gal using Lipofectamine Plus (Invitrogen) according to the
vendor’s protocol. Reporter gene activities were normalized to
cotransfected controls and all results represent three averaged ex-
periments, each performed in triplicate.
 
Western Blot and Prostaglandin Analysis.
 
Confluent cell mono-
layers were lysed in RIPA buffer and denatured lysates (50 
 
 
 
g)
were separated by 10% SDS-PAGE as described previously (6). Af-
ter electrophoresis, proteins were transferred to PVDF membranes
and probed with antibodies against COX-2 (C-20), TIA-1 (C-20),
TIAR (C-18), HuR (3A2), and 
 
 
 
-actin (Santa Cruz). PGE
 
2
 
 levels
were assayed in culture media by ELISA (R&D Systems) as de-
scribed previously (6). Relative PGE
 
2
 
 levels were normalized to
total protein and are the average of triplicate experiments.
 
mRNA Analysis.
 
RNase protection assays were used to exam-
ine COX-2, c-myc, and 28S RNA levels in 10 
 
 
 
g of total RNA
as described previously (4). RNA decay experiments were initiated
by adding ActD (5 
 
 
 
g/ml) to the growth medium. RT-PCR
analysis was conducted using primers designed to amplify the en-
tire coding region of human TIA-1 (1139 bp) and a region of
 
 
 
-actin (514 bp) from oligo(dT)-primed cDNA as described (4).
 
Analysis of TIA-1 Protein/RNA Interactions.
 
Radiolabeled
TIA-1 protein was prepared by in vitro transcription/translation
of the human TIA-1 cDNA to incorporate 
 
35
 
S-methionine. In
vitro transcription reactions incorporating biotin-16-UTP into
sense RNAs for COX-2 and GM-CSF AREs (4) were performed
using the MAXIscript kit (Ambion) according to the conditions
specified by the manufacturer. pTRI-CAT (Ambion) was used to
create a control CAT RNA. Biotin-labeled RNA (10 
 
 
 
g/well)
was immobilized to NeutrAvidin-coated polystyrene 96-well
strip plates blocked with BSA (Pierce Chemical Co.) in 50 
 
 
 
l of
1
 
 
 
 RNA binding buffer (4) for 2 h at 25
 
 
 
C and then washed
three times with binding buffer. 
 
35
 
S-labeled TIA-1 protein (2 
 
 
 
l/
well) was added in binding buffer in a total volume of 50 
 
 
 
l. Each
well was incubated for 30 min and next 5 mg/ml heparin was
added and incubation continued for 15 min. Wells were washed
with binding buffer and RNA-bound TIA-1 was extracted and
electrophoresed in 10% SDS-PAGE. The 
 
35
 
S-labeled TIA-1 pro-
tein was visualized by autoradiography and quantitated by phos-
phorimage analysis.
In vitro UV-light cross-linking/label transfer experiments
were conducted as described (4) to examine cytoplasmic protein
binding to in vitro transcribed 
 
32
 
P-labeled COX-2 ARE RNA.
Immunoprecipitation of TIA-1 bound to the COX-2 ARE was
performed as described previously (6) using 1 
 
 
 
g of polyclonal
anti-TIA-1 antibody (Santa Cruz Biotechnology, Inc.) or iso-
type-matched IgG.
In vivo cross-linking analysis was performed as described (11).
Confluent monolayers of HT29 and LoVo (5 
 
 
 
 10
 
6
 
) cells were
UV-irradiated in a Stratalinker 2400 (Stratagene) for 3 min and
cytoplasmic poly(A) mRNA was isolated using Oligotex beads ac-
cording to the vendor’s protocol. After RNase digestion, samples
were separated on 10% SDS-PAGE, transferred to PVDF mem-
branes, and TIA-1 detection was determined by Western blot.
 
Polysome Profile Analysis.
 
Analysis of polysomes by sucrose
density gradient centrifugation was done as described (12). Cyto-
plasmic lysates were layered on a 15–40% linear sucrose gradient
and centrifuged at 38,000 rpm for 127 min at 4
 
 
 
C in a Beckman
SW40Ti rotor. The RNA from each gradient fraction (500 
 
 
 
l)
was extracted by phenol/chloroform and aliquots were analyzed
on a 1% agarose gel to resolve the polysome profile. COX-2 and
GAPDH mRNA levels in each fraction were determined as de-
scribed previously (4).
 
Results and Discussion
 
The Translational Silencer TIA-1 Binds the COX-2 AU-
Rich Element.
 
Best characterized for their ability to medi-
ate rapid mRNA decay, AREs also function to regulate
gene expression by acting as translation inhibitory elements
(13, 14). Recent evidence has demonstrated that a central
point in COX-2 regulation is mediated through the con-
served ARE present in the 3
 
 
 
UTR (4, 5, 7). In normal
cells, the COX-2 ARE can serve as a translation inhibitory
element to specifically attenuate protein levels independent
of rapid mRNA decay (4). We demonstrated that a com-
plex of proteins with molecular weights ranging from 35 to
90-kD regulates posttranscriptional control by binding the
ARE-containing 3
 
 
 
UTR of COX-2 (4). However, the
trans-acting factors have not been definitively characterized
and their role in regulating COX-2 expression is currently
unknown. The TIA-1 protein functions as a translational
silencer of nonheat shock mRNAs in cells subjected to en-
vironmental stress (15, 16). More pertinent to this study,
this ubiquitously expressed RNA-binding protein has been
demonstrated to confer translational repression of TNF-
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through binding of the ARE present within the TNF-
 
 
 
3
 
 
 
UTR (9).
We sought to determine if the COX-2 ARE is a target
of TIA-1. RNA-binding assays were conducted using sense
RNA for COX-2 and GM-CSF AREs (4) that were tran-
scribed to incorporate biotin-16-UTP. 
 
35
 
S-labeled TIA-1
was incubated with immobilized RNA and allowed to
bind. TIA-1 bound to RNA was detected by SDS-PAGE
(Fig. 1 A). Approximately 25% of the input TIA-1 was ob-
served to bind the COX-2 ARE; similar levels of binding
(29%) were detected using the well-characterized ARE
from GM-CSF. A low level of background TIA-1 binding
was detected in reactions using a control biotin-labeled
RNA of similar length (CAT) or in the absence of RNA
ligand (-RNA).
To determine if TIA-1 protein is a component of the
COX-2 ARE-binding complex (4), the RNA-binding
proteins present in crude (S10) cytoplasmic extracts were
covalently cross-linked to the 
 
32
 
P-labeled COX-2 ARE
through UV-light irradiation and then subjected to TIA-1
immunoprecipitation (Fig. 1 B). A protein complex rang-
ing from 35 to 90-kD present in HeLa cell lysates associates
with the COX-2 ARE (4). Specific immunoprecipitation
of UV-cross-linked lysates using anti-TIA-1 antibody iden-
tified a 
 
32
 
P-labeled polypeptide migrating at 45-kD. No
cross-linked proteins were immunoprecipitated using iso-
type-matched IgG. Similar results were obtained with im-
munoprecipitation when using 
 
32
 
P-labeled GM-CSF ARE
(unpublished data). These findings indicate that TIA-1 is a
component of the COX-2 ARE-binding protein complex
and has an ability to interact with other AREs (9, 14).
 
TIA-1 Protein Regulates COX-2 Expression.
 
The ability
of TIA-1 to bind the COX-2 ARE implicates it in COX-2
posttranscriptional regulation and suggests that defects in
TIA-1 binding may alter normal COX-2 expression. To
examine potential TIA-1 effects on COX-2 expression,
endogenous COX-2 mRNA and protein expression were
compared in wild-type and TIA-1–deficient (TIA-1
 
 
 
/
 
 
 
)
mouse embryonic fibroblasts (MEFs). Early passage MEFs
derived from wild-type and TIA-1
 
 
 
/
 
 
 
 mice were cultured
under identical conditions in the presence of serum and as-
sayed for the expression of COX-2 protein. As shown in
Fig. 2 A, an 
 
 
 
two- to threefold increase in COX-2 pro-
tein expression was consistently observed in the TIA-1
 
 
 
/
 
 
 
MEFs. We and others previously demonstrated the ability
of the ARE-binding proteins TIAR and HuR to regulate
the expression of COX-2 and other ARE-containing
mRNAs (6, 14). The levels of the ARE-binding proteins
TIAR and HuR were examined in both wild-type and
TIA-1
 
 
 
/
 
 
 
 MEFs. No differences in the levels of TIAR or
HuR were detected in either cell type, whereas TIA-1 was
detected only in the wild-type cells (Fig. 2 A). In addition,
cyclooxygenase activity present in TIA-1
 
 
 
/
 
 
 
 MEFs pro-
Figure 1. TIA-1 binds the COX-2 ARE. (A) Biotin-labeled RNA
containing the COX-2 ARE, GM-CSF ARE, or control CAT RNA
were incubated with in vitro translated 35S-labeled TIA-1 protein. TIA-1
bound to immobilized RNA was detected by electrophoresis on SDS-
PAGE. Total TIA-1 protein used per reaction is shown in the first lane
and nonspecific binding is shown in the second lane. (B) Cytoplasmic
HeLa lysate was incubated with 32P-labeled COX-2 ARE and bound
proteins were cross-linked to RNA by UV-light irradiation. Reactions
were immunoprecipitated using anti-TIA-1 antibody ( -TIA-1) or IgG.
The -Ab lane shows the bound proteins in 1/10 of the cross-linking reac-
tion before immunoprecipitation. Molecular weight standards (kD) are
listed on the left.
Figure 2. TIA-1 inhibits COX-2 expression. (A) MEFs derived from
wild-type or TIA-1 /  mice were examined for COX-2 protein expres-
sion by Western blot. Molecular weight standards (kD) are listed on the
left. (B) COX activity measured by PGE2 production in wild-type (open
bars) and TIA-1 /  (filled bars) MEFs treated with carrier or NS-398. (C)
Western blot of COX-2 protein in TIA-1 /  MEFs stably transfected
with a TIA-1 expression construct or vector.T
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duced approximately twofold more prostaglandin PGE
 
2
 
than wild-type MEFs (Fig. 2 B). Blockade of COX-2 ac-
tivity with the COX-2 inhibitor NS-398 left trace levels of
PGE
 
2
 
 in both cell lines. To determine if down-regulation
of COX-2 could be restored, TIA-1
 
 
 
/
 
 
 
 MEFs were stably
transfected with a TIA-1 expression construct. In TIA-1
 
 
 
/
 
 
 
MEFs cells stably expressing TIA-1, the expression of
COX-2 protein was only one-half of that observed in vec-
tor-transfected cells (Fig. 2 C). We conclude that the dif-
ference in COX-2 expression detected between TIA-1
 
 
 
/
 
 
 
and wild-type cells resulted from the absence of TIA-1.
To determine whether the enhanced expression of
COX-2 protein observed in TIA-1
 
 
 
/
 
 
 
 cells is a result
of increased 
 
COX-2
 
 transcription, the steady-state level of
COX-2 mRNA in TIA-1
 
 
 
/
 
 
 
 and wild-type MEFs was ex-
amined. Growth in serum-containing media resulted in
similar steady-state COX-2 mRNA observed in both cells
(Fig. 3 A). In addition, a reporter construct containing a
1.8-kb fragment of the COX-2 promoter demonstrated
similar levels of 
 
COX-2
 
 transcription in both cell types
(Fig. 3 B). MEFs grown under serum-free conditions re-
sulted in low-to-undetectable COX-2 mRNA and protein
expression, suggesting that the induction of COX-2 tran-
scription in both cell types is a result of growth factor stim-
ulation (unpublished data). As both the wild-type and TIA-
1
 
 
 
/
 
 
 
 MEFs displayed similar levels of COX-2 mRNA, it is
unlikely that loss of TIA-1 altered the rapid decay of
COX-2 mRNA. To directly assess this, we measured the
half-life of endogenous COX-2 mRNA in both cell types.
The results shown in Fig. 3 C demonstrate that rapid
COX-2 mRNA decay is seen in both wild-type (t
 
1/2
 
 
 
 
 
 14
min) and TIA-1
 
 
 
/
 
 
 
 MEFs (t
 
1/2
 
 
 
 
 
 15 min). Rapid turnover
of constitutively expressed c-myc mRNA was seen in both
wild-type and TIA-1
 
 
 
/
 
 
 
 cells (t
 
1/2
 
 
 
 
 
 15 and 16 min, re-
spectively). These results demonstrate that absence of TIA-1
does not alter either the transcription of the 
 
COX-2
 
 gene
or the stability of its mRNA. This is consistent with the
ability of AREs present within various cytokine mRNAs to
act as translation inhibitory elements similar to the COX-2
ARE. In these studies, the mRNA levels of the respective
genes were virtually unaffected, demonstrating the ability
of AREs to act as translation inhibitory elements by impos-
ing translational blockade (13, 14).
 
Loss of Translational Control Promotes COX-2 Expression in
Colon Cancer Cells.
 
It has been shown that constitutive
transcription of 
 
COX-2
 
 initiates unregulated expression of
the protein in colon cancer (3), yet growing evidence sup-
ports the notion that posttranscriptional regulation of
COX-2 expression also plays a central role (4, 5, 7). Cellu-
lar defects in this facet of gene regulation result in elevated
COX-2 protein expression, which in turn promotes cell
growth through enhanced prostaglandin synthesis (5, 6).
Previously, we demonstrated that altered recognition of the
COX-2 ARE in colon cancer cells correlates with en-
hanced expression of COX-2 (6). We postulated that the
binding of cellular trans-acting regulatory proteins directly
influences stability and translation of COX-2 mRNA. The
human colon cancer cell lines HT29 and LoVo display
constitutive transcription of 
 
COX-2
 
 (6). Yet, HT29 cells
have six- to sevenfold more COX-2 protein and associated
prostaglandin synthesis than LoVo cells (6). This increase in
COX-2 protein despite constitutive transcription of COX-2
mRNA in both cell types suggests that the translational
control of COX-2 is altered in the HT29 cells.
This was directly examined through polysome profile
analysis of the translational status of COX-2 mRNA in co-
lon cancer cells. HT29 and LoVo cytoplasmic extracts were
fractionated over sucrose gradients and evaluated for differ-
ences in distribution of COX-2 mRNA. As shown in Fig.
4, COX-2 transcripts were primarily associated with the
nonpolysomal fractions in LoVo cells. This is consistent
with polysome profiles demonstrating the ability of func-
tional AREs to exclude transcripts from polysome associa-
tion (17) and suggests that the COX-2 ARE acts similarly
to block mRNA translation at the initiation step involving
the formation of 80S particles (18). In contrast to this, there
is a clear shift of COX-2 mRNA toward the polysomal
fractions in the HT29 cells suggesting the loss of ARE-
mediated translational repression. Control polysome profile
of endogenous GAPDH mRNA showed similar profiles for
each cell type (unpublished data). These results reflect the
increased levels of COX-2 protein expression observed in
HT29 cells when compared with LoVo cells (6) and agree
Figure 3. TIA-1 does not alter rapid COX-2 mRNA decay. (A)
Steady-state COX-2 mRNA in wild-type and TIA-1 /  MEFs levels
were detected by RNase protection assay. (B) COX-2 transcription was
determined using a luciferase reporter construct containing either the
COX-2 promoter (filled bars) or vector (open bars) cotransfected with
pSV- gal. (C) COX-2 and c-myc mRNA half-life experiments were ini-
tiated by adding 5  g/ml ActD to MEFs for the indicated times and de-
cay was analyzed by RNase protection assay. 28S RNA is shown as a
control for RNA loading.T
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with previous findings demonstrating the ability of the
COX-2 3 UTR to block mRNA translation in cells dis-
playing ARE-mediated posttranscriptional regulation of
COX-2 (4).
Defective TIA-1 Binding Promotes COX-2 Expression in
Colon Cancer Cells. Based on these results that implicated
TIA-1 as a translational silencer of COX-2 expression, we
sought to determine whether defects in its ability to bind
the COX-2 ARE contribute to enhance COX-2 transla-
tion and promote overexpression in HT29 colon cancer
cells. The ability of TIA-1 to bind the COX-2 ARE was
examined by immunoprecipitation of cross-linked lysates
from HT29 and LoVo cells. Immunoprecipitation of la-
beled proteins of 45-kD were detected in both LoVo and
control HeLa cells; however, no detectable binding was
observed in lysates from HT29 cells (Fig. 5 A). This appar-
ent defect is not due to a lack of expression in HT29 cells
since similar levels of TIA-1 mRNA and protein were de-
tected in all cells (Fig. 5 B).
The lack of ARE-binding by TIA-1 in HT29 cells was
examined further by UV-cross-linking studies of TIA-1
with poly(A) RNA in intact cells. After exposure to UV-
light, poly(A) RNA was isolated from equal numbers of
HT29 and LoVo cells. The cross-linked RNA-binding
proteins were separated by SDS-PAGE and TIA-1 was de-
tected by immunoblotting. Consistent with the immuno-
precipitation results, TIA-1 protein was cross-linked to
mRNA in LoVo cells and there was no association of TIA-1
with mRNA in HT29 cells (Fig. 5 C). TIA-1 is known
to have alternative splicing (19) which accounts for the pro-
tein doublet. The slightly higher mobility of cross-linked
TIA-1 is presumably due to covalent attachment of the
RNA moiety; no protein binding to mRNA was detected
when UV-irradiation was omitted (unpublished data).
Figure 4. COX-2 polysome profile in colon cancer cells. HT29 and
LoVo cytoplasmic lysates were fractionated on a continuous 15–40% su-
crose gradient. Polysome profiles were obtained by running RNA samples
from each fraction on an agarose gel to identify the 40S and 60S ribosomal
subunits along with 80S and polysomes (bottom panel). The distribution
of COX-2 mRNA from HT29 cells (filled circles) and LoVo cells (open
triangles) was detected by RNase protection assay of gradient fractions.
Figure 5. Deficient binding of TIA-1 occurs in HT29 cells. (A) Cyto-
plasmic protein complexes from control HeLa, HT29, and LoVo cells
bound to the 32P-labeled COX-2 ARE were UV-cross-linked and im-
munoprecipitated using TIA-1 antibody. (B) RT-PCR (left panel) and
Western blot (right panel) analysis of TIA-1 and  -actin from control
HeLa, HT29, and LoVo cells. (C) In vivo cross-linking of TIA-1 protein
to poly(A) mRNA was examined in HT29 and LoVo cells.T
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As LoVo cells display intact TIA-1 binding and transla-
tional repression of COX-2, we attribute loss of ARE-
mediated translational regulation in HT29 cells, in part, to
defects in the ability of TIA-1 to bind the COX-2 ARE.
Accordingly, inhibition of TIA-1 activity using a domi-
nant-negative mutant of TIA-1 promotes expression of
COX-2 in LoVo cells (unpublished data). Based on this ev-
idence, it is likely that TIA-1 represses COX-2 mRNA
translation through the assembly of nonpolysomal com-
plexes, similar to that seen with TNF-  transcripts (16). In-
terestingly, lack of TIA-1 expression does not explain the
differences in COX-2 expression between HT29 and LoVo
cells and ectopic overexpression of TIA-1 in HT29 cells
does not promote COX-2 translational repression (unpub-
lished data). These findings suggest that binding of TIA-1
to the COX-2 ARE is influenced by other factors. Our
previous observations demonstrated increased expression of
the ARE-binding protein HuR in HT29 cells, resulting in
a lengthened COX-2 mRNA half-life (6). This suggests
that limited TIA-1 binding observed in HT29 cells may be
a direct result of increased competition for ARE-binding
sites due to elevated HuR levels. With regard to this, we
also observe decreased ARE-binding of the TIA-1–related
protein TIAR in HT29 cells (unpublished data). More im-
portantly, this effect may extend to colon tumors where in-
creased HuR levels are also observed (6). Consistent with
this notion is the ability of the ARE-binding protein AUF1
to promote tumorigenesis when overexpressed in mice (20)
and the observed competition for ARE-binding between
HuR and TTP proteins after T lymphocyte activation (21).
The results presented here expand on our original obser-
vations linking tumorigenesis to the loss of posttranscrip-
tional regulation of COX-2 expression. It is well accepted
that transcriptional activation of COX-2 is an early event in
the initiation of colon tumorigenesis (3, 6). However, en-
hanced expression of COX-2 protein may also require ab-
errant posttranscriptional regulation in many instances. Our
results demonstrate a novel link between control of COX-2
expression and the RNA-binding protein TIA-1. While
other components of ARE-mediated regulation remain to
be elucidated, these studies implicate a role for TIA-1 as a
tumor suppressor in its ability to function as a translational
silencer of COX-2. Defects in TIA-1 activity may result in
unregulated expression of COX-2 during the later stages of
tumor progression.
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